- Hemostemix (HEM) has appointed Dr. Ernst von Schwarz, MD, Ph.D., FESC, FACC, FSCAI to its Scientific Advisory Board
- Dr. von Schwarz is a renowned, triple board certified clinical and academic cardiologist and clinical professor of medicine
- Hemostemix is a clinical-stage biotechnology company
- Hemostemix Inc. (HEM) opened trading at C$0.195
Hemostemix (HEM) has appointed Dr. Ernst von Schwarz, MD, Ph.D., FESC, FACC, FSCAI to its Scientific Advisory Board.
Dr. von Schwarz is a US-based world-renowned, triple board certified clinical and academic cardiologist and clinical professor of medicine at UCLA and UC Riverside. He joined Cedars Sinai Medical Center and UCLA as Director of the Cardiac Device Program in 2006. He was appointed director of cardiology at the Heart Institute of Southern California Hospital Culver City in 2015 and chairman of Pacific Heart Medical Group, and medical director of Heart Stem Inc. in 2016.
Dr. von Schwarz has published over 150 scientific papers in international peer-reviewed medical journals, as well as books and book chapters in cardiovascular medicine. In May 2022, Dr. Schwarz published Secret World of Stem Cell Therapy: What YOU Need to Know about the Health, Beauty, and Anti-Aging Breakthrough.
Dr. von Schwarz is board certified in internal medicine by the American Board of Internal Medicine and in cardiology/cardiovascular diseases by the American Board of Internal Medicine in Cardiology/Cardiovascular Diseases. His primary clinical interests are end-stage heart failure, cardiac transplantation, interventional cardiology and sexual function in cardiac disease.
Dr. von Schwarz earned his medical degree from Philipps-University in Marburg, Germany and the University of Vienna, Austria. He received his doctorate from the University of Technology in Aachen, Germany.
Dr. von Schwarz commented on the opportunity.
“I have worked in the field of heart-based stem cell science my whole career, and I find ACP-01’s unique properties, safety profile and statistically significant ejection fraction improvement to be very interesting and very promising. I look forward to SAB collaboration, clinical trial work as a lead investigator, and becoming a compassionate treatment center as soon as it is practical to do so.”
“Hemostemix is delighted to welcome Dr. Schwarz to our SAB,” stated Thomas Smeenk, CEO of Hemostemix. “Within weeks of the release of our cardiomyopathy study results, we attracted the best regenerative medicine heart specialists in the world because they agree ACP-01 promises to be the first-to-patient stem cell treatment for cardiomyopathy.”
Hemostemix is a clinical-stage biotechnology company. The company’s principal business activity is to develop, manufacture, and commercialize blood-derived cell therapies for medical conditions.
Hemostemix Inc. (HEM) opened trading at C$0.195.
